News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. (RNN) Reports First Quarter 2014 Financial Results And Pipeline Update



5/15/2014 9:56:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended March 31, 2014.

“We continue to enroll patients in each of our three clinical trials as expected, and as planned for,” stated Rexahn’s Chief Executive Officer, Peter D Suzdak, Ph.D. “By the end of 2014, we expect to achieve key milestones in each trial.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES